CN101612234A - A kind of method of Chinese medicine processing - Google Patents
A kind of method of Chinese medicine processing Download PDFInfo
- Publication number
- CN101612234A CN101612234A CN200910115695A CN200910115695A CN101612234A CN 101612234 A CN101612234 A CN 101612234A CN 200910115695 A CN200910115695 A CN 200910115695A CN 200910115695 A CN200910115695 A CN 200910115695A CN 101612234 A CN101612234 A CN 101612234A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- raw material
- fructus aurantii
- hesperetin
- pyranglucoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000012545 processing Methods 0.000 title claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 37
- 238000001764 infiltration Methods 0.000 claims abstract description 16
- 230000008595 infiltration Effects 0.000 claims abstract description 16
- 238000005266 casting Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000459479 Capsula Species 0.000 claims abstract description 9
- 238000002791 soaking Methods 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000010209 hesperetin Nutrition 0.000 abstract description 23
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 abstract description 22
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 abstract description 22
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 abstract description 22
- 229960001587 hesperetin Drugs 0.000 abstract description 22
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 6
- 238000003672 processing method Methods 0.000 abstract description 6
- 241000723346 Cinnamomum camphora Species 0.000 abstract description 3
- 150000002387 hesperetin Chemical class 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007803 cold maceration Methods 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- -1 methoxyl group Chemical group 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of method of Chinese medicine processing, particularly to the Chinese medicine processing method of Fructus Aurantii.A kind of method of Chinese medicine processing, cut out the capsula interna of raw material of Chinese medicine with cutter, clean silt, water infiltration 6-24 hour, raw material of Chinese medicine after soaking into the extruding of the casting die of irony again with yoke on the raw material of Chinese medicine, was placed 6-8 days in 30-35 ℃, relative humidity are the environment of 60-80%, take out section earlier, dry again and obtain the prepared slices of Chinese crude drugs; Raw material of Chinese medicine wherein is a Fructus Aurantii.Use the Fructus Aurantii after Chinese medicine processing method of the present invention is handled, can find that through detecting hesperetin is arranged-existence of 7-O-β-D-pyranglucoside.The material of hesperetin class has certain efficacy of drugs usually, and hesperetin-7-O-β-D-pyranglucoside has stronger pharmacologically active.With Fructus Aurantii is that the Chinese medicine of representative is placed under the hot and humid environment and handles, and to adopt the casting die typing of irony be typical Camphor tree group method concocting method.
Description
Technical field
The present invention relates to a kind of method of Chinese medicine processing, mainly is the Chinese medicine processing method at Fructus Aurantii.
Background technology
Different processing procedures are influential to the variation of Chinese medicine ingredients, and then influence pharmaceutical properties and quality.For example just pointed out that different processing procedures are influential to the Fructus Aurantii quality in the article of " different processing procedures are to the research of Fructus Aurantii quality influence " of the 23rd volume 4 phases record in " practical Chinese medicine magazine " April in 2007, with the content of water-soluble extractives in cold-maceration mensuration Fructus Aurantii decoction pieces and the different processed product, with content of total flavone in determined by ultraviolet spectrophotometry Fructus Aurantii decoction pieces and the different processed product.The result; The content of stir-baked Fructus Aurantii in bran, bran baking Fructus Aurantii water-soluble extractives is all apparently higher than the Fructus Aurantii decoction pieces, but total yellow content of succeeding all slightly descends.Relatively stir-baked Fructus Aurantii in bran and bran baking Fructus Aurantii is found, two kinds of processing procedures are to the active constituent content influence of Fructus Aurantii.
Traditional Fructus Aurantii processing technique is: gets the Fructus Aurantii crude drug, removes impurity, soaked about 1 hour, clean and pull out with clear water, and moistening 24-28 hour, shave when extremely interior free surface moisture is consistent, drying, the flesh that sieve goes to come off is examined.Traditional Fructus Aurantii processing technique is not concocted under hot and humid condition, and internal component hesperetin-7-O-β-D-pyranglucoside do not occur through detecting after changing not obvious, traditional Fructus Aurantii process of preparing Chinese medicine end.
The material of hesperetin, glycoside has certain drug action; for example " Separation of Natural Products " rolled up for 6 phases in 2006 4; " 1-3; the drug efficacy study of 8 hesperetins and application " put down in writing drug efficacy study and the application of Sichuan University's life sciences institute living resources and key lab of the ecological environment Ministry of Education to hesperetin: hesperetin (Hesperetin) is ubiquitous a kind of flavonoid material in the orange, has antioxidation, anti-inflammatory, the reaction of resistance state property, blood fat reducing, protection cardiovascular and antineoplastic drug action.
" Nanjing Normal University's journal: natural science edition " 2008 31 3 phases of volume, " hesperetin is to the influence of vascular endothelial cell NO secretory function " put down in writing the influence of hesperetin to Human umbilical vein endothelial cells (HUVECs) NO secretory function, inquires into its mechanism of action.Adopt the DAN method to measure the level of HUVECs secretion NO for this reason, estimate the estrogenic activity of hesperetin with short proliferation experiment of human breast carcinoma MCF-7 cell (estrogen receptor positive) and reporter gene model experiment.The result is presented under the lower condition of endogenous estrogen level, and hesperetin can promote HUVECs secretion NO, and be dose dependent in 12.5-100 μ moVL concentration range.This effect can be by estrogen receptor antagon ICI182, and 780 and the actinomycin D blocking-up.Hesperetin and E2 do the time spent simultaneously, and HUVECs secretion NO level is done the time spent separately than both and significantly descended.And under endogenous estrogen level conditions of higher, hesperetin suppresses HUVECs secretion NO.Hesperetin can promote the MCF-7 cell proliferation, and can be by ICI182,780 blocking-up fully, simultaneously, hesperetin can part antagonism E2 to the short proliferation function of MCF-7 cell.In addition, hesperetin can be induced the reporter gene expression of ERa control.Thereby can think that hesperetin belongs to the estrogen receptor partial agonist, vascular endothelial cell NO secretory function is had regulating action, its mechanism relates to the estrogen receptor signal pathway and genetic transcription is regulated.
Summary of the invention
The object of the present invention is to provide a kind of method of Chinese medicine processing.
Technical scheme of the present invention:
A kind of method of Chinese medicine processing cuts out the capsula interna of raw material of Chinese medicine with cutter, cleans silt, water infiltration 6-24 hour, with the raw material of Chinese medicine after the casting die extruding infiltration of irony, again with yoke on the raw material of Chinese medicine, under hot and humid environment, concoct, take out section earlier, dry again and obtain the prepared slices of Chinese crude drugs; Raw material of Chinese medicine wherein is a Fructus Aurantii.
A kind of method of Chinese medicine processing, cut out the capsula interna of raw material of Chinese medicine with cutter, clean silt, water infiltration 6-24 hour, raw material of Chinese medicine after soaking into the extruding of the casting die of irony again with yoke on the raw material of Chinese medicine, was placed 6-8 days in 30-35 ℃, relative humidity are the environment of 60-80%, take out section earlier, dry again and obtain the prepared slices of Chinese crude drugs; Raw material of Chinese medicine wherein is a Fructus Aurantii.
A kind of method of Chinese medicine processing, cut out the capsula interna of raw material of Chinese medicine with cutter, clean silt, water infiltration 6-24 hour, with the raw material of Chinese medicine after the casting die extruding infiltration of irony, again with yoke on the raw material of Chinese medicine, in being the environment of 60-80%, 30-35 ℃, relative humidity placed 6-8 days, take out section earlier, dry the prepared slices of Chinese crude drugs that obtain containing hesperetin-7-O-β-D-pyranglucoside again, raw material of Chinese medicine wherein is a Fructus Aurantii.
The casting die of irony can be the weight that metallic iron is made, such as anchor.Raw material of Chinese medicine after the infiltration is finalized the design than being easier to anchor extruding back.
With Fructus Aurantii is that the Chinese medicine of representative is placed under the hot and humid environment and handles, and to adopt the casting die typing of irony be typical Camphor tree group method concocting method, and Camphor tree group method concocting method is the characteristic Chinese medicine processing method of passing on from generation to generation always, does not announce to the external world.
Owing to adopt the process of preparing Chinese medicine method under the hot and humid condition of the present invention, promoted the variation of Fructus Aurantii internal component greatly, use the Fructus Aurantii after Chinese medicine processing method of the present invention is handled, can find that through detecting hesperetin is arranged-existence of 7-O-β-D-pyranglucoside.And hesperetin-7-O-β-D-pyranglucoside was never reported in the Fructus Aurantii composition that in the past document relates to.This proves that Chinese medicine processing method of the present invention has conclusive effect to the variation of the internal component of Fructus Aurantii really.
The hesperetin of hesperetin-7-O-β-D-pyranglucoside and existing bibliographical information, the material of glycoside have similar chemical constitution, thereby similar efficacy of drugs is also arranged.
Hesperetin-7-O-β-concrete the detection method of D-pyranglucoside: the chemical constitution study of concocting the back Fructus Aurantii, have two new chromatographic peaks to produce (seeing No. 5 peaks and No. 6 peaks among Fig. 2) in the high-efficient liquid phase chromatogram (HPLC) discovery is concocted Fructus Aurantii through method of the present invention after, the present invention carries out extraction separation to the chemical constituent in the processed product of Fructus Aurantii and adopts
1H-NMR,
13Spectrum Analysis technology such as C-NMR, HMQC, HMBC identify that in conjunction with the structure of the chemical compound that physicochemical property obtains separation wherein No. 6 peaks are hesperetin-7-O-β-D-pyranglucoside.
The structure of hesperetin-7-O-β-D-glucopyranoside compound is identified: white powder (ethanol), mp223-225 ℃, AlCl
3Its fluorescence is significantly strengthened.
1H-NMR (DMSO-d6,400MHz) spectrum δ: 5.50 (1H, dd, J=3,9.7Hz), 2.76 (J=14.5Hz), 3.29 (1H, d J=12.9Hz) are 2H on the typical flavanone parent nucleus, the proton signal of 3H for 1H, d.(1H, s), 6.12 (1H is 5,7 two to replace H-6 and two proton signals of H-8 on the flavone A rings s) to δ 6.14, and (3H m) is 3 proton signals on the B ring to δ 6.95-6.87.(1H s) is the 5-OH signal to δ 12.05, and (1H s) is the phenolic hydroxyl group proton signal to δ 9.16, and (3H s) is proton on the methoxyl group to δ 3.76.
13The carbon spectrum data contrast basically identical of the hesperetin 7-O-β-D-pyranglucoside in C-NMR data (seeing Table 1) and the document, by
1H-
1HCOSY, HMQC, HMBC spectrum also confirm consistent with bibliographical information, are hesperetin 7-O-β-D-pyranglucoside so identify this chemical compound.
Table 1
Advantage of the present invention: by under hot and humid environment, concocting, can obtain containing the Fructus Aurantii decoction pieces of new hesperetin-7-O-β-D-pyranglucoside material, the material of hesperetin classification has certain pharmaceutical properties usually, and hesperetin 7-O-β-D-pyranglucoside has stronger pharmacologically active.
Description of drawings
Fig. 1 is that Fructus Aurantii gives birth to product HPLC figure
Fig. 2 is that Fructus Aurantii is through the processed product HPLC figure after concocting
Fig. 3 is the molecular structure of hesperetin 7-O-β-D-pyranglucoside
Specific embodiment
A kind of method of Chinese medicine processing, cut out the capsula interna of raw material of Chinese medicine with cutter, clean silt, water infiltration 6 hours is with the raw material of Chinese medicine after the casting die extruding infiltration of irony, again with yoke on the raw material of Chinese medicine, in being 60% environment, 30 ℃, relative humidity placed 8 days, take out section earlier, dry the prepared slices of Chinese crude drugs that obtain containing hesperetin-7-O-β-D-pyranglucoside again, raw material of Chinese medicine wherein is a Fructus Aurantii.
A kind of method of Chinese medicine processing, cut out the capsula interna of raw material of Chinese medicine with cutter, clean silt, water infiltration 24 hours is with the raw material of Chinese medicine after the casting die extruding infiltration of irony, again with yoke on the raw material of Chinese medicine, in being 80% environment, 35 ℃, relative humidity placed 6 days, take out section earlier, dry the prepared slices of Chinese crude drugs that obtain containing hesperetin-7-O-β-D-pyranglucoside again, raw material of Chinese medicine wherein is a Fructus Aurantii.
Embodiment 3
A kind of method of Chinese medicine processing, cut out the capsula interna of raw material of Chinese medicine with cutter, clean silt, water infiltration 12 hours is with the raw material of Chinese medicine after the casting die extruding infiltration of irony, again with yoke on the raw material of Chinese medicine, in being 70% environment, 33 ℃, relative humidity placed 7 days, take out section earlier, dry the prepared slices of Chinese crude drugs that obtain containing hesperetin-7-O-β-D-pyranglucoside again, raw material of Chinese medicine wherein is a Fructus Aurantii.
Claims (2)
1, a kind of method of Chinese medicine processing, it is characterized in that: the capsula interna that cuts out raw material of Chinese medicine with cutter, clean silt, water infiltration 6-24 hour, with the raw material of Chinese medicine after the casting die extruding infiltration of irony,, under hot and humid environment, concoct again with yoke on the raw material of Chinese medicine, cut into slices after drying in taking-up wash clean surface; Raw material of Chinese medicine wherein is a Fructus Aurantii.
2, a kind of method of Chinese medicine processing, it is characterized in that: the capsula interna that cuts out raw material of Chinese medicine with cutter, clean silt, water infiltration 6-24 hour, raw material of Chinese medicine after soaking into the extruding of the casting die of irony again with yoke on the raw material of Chinese medicine, was placed 14-20 days in 30-35 ℃, relative humidity are the environment of 60-80%, cut into slices after drying in taking-up wash clean surface; Raw material of Chinese medicine wherein is a Fructus Aurantii.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101156957A CN101612234B (en) | 2009-07-15 | 2009-07-15 | Traditional Chinese medicine processing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101156957A CN101612234B (en) | 2009-07-15 | 2009-07-15 | Traditional Chinese medicine processing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101612234A true CN101612234A (en) | 2009-12-30 |
| CN101612234B CN101612234B (en) | 2011-08-17 |
Family
ID=41492241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101156957A Active CN101612234B (en) | 2009-07-15 | 2009-07-15 | Traditional Chinese medicine processing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101612234B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780168A (en) * | 2010-03-08 | 2010-07-21 | 江西中医学院 | Processing method of Fructus Aurantii |
| CN104289156A (en) * | 2014-10-27 | 2015-01-21 | 甘肃中医学院 | Method for softening traditional Chinese medicinal material before slicing |
| CN104490960A (en) * | 2015-01-20 | 2015-04-08 | 黑龙江中医药大学 | Radix sileris processing method |
| CN106511556A (en) * | 2016-11-10 | 2017-03-22 | 四川涪丰药业有限公司 | Processing method of fructus aurantii |
| CN115518104A (en) * | 2021-06-25 | 2022-12-27 | 广州中医药大学(广州中医药研究院) | Method for processing fructus aurantii |
-
2009
- 2009-07-15 CN CN2009101156957A patent/CN101612234B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780168A (en) * | 2010-03-08 | 2010-07-21 | 江西中医学院 | Processing method of Fructus Aurantii |
| CN101780168B (en) * | 2010-03-08 | 2012-05-30 | 江西中医学院 | Processing method of Fructus Aurantii |
| CN104289156A (en) * | 2014-10-27 | 2015-01-21 | 甘肃中医学院 | Method for softening traditional Chinese medicinal material before slicing |
| CN104490960A (en) * | 2015-01-20 | 2015-04-08 | 黑龙江中医药大学 | Radix sileris processing method |
| CN104490960B (en) * | 2015-01-20 | 2018-06-22 | 黑龙江中医药大学 | Windproof processing method |
| CN106511556A (en) * | 2016-11-10 | 2017-03-22 | 四川涪丰药业有限公司 | Processing method of fructus aurantii |
| CN115518104A (en) * | 2021-06-25 | 2022-12-27 | 广州中医药大学(广州中医药研究院) | Method for processing fructus aurantii |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101612234B (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Woźniak et al. | Belamcandae chinensis rhizoma–a review of phytochemistry and bioactivity | |
| CN101612234B (en) | Traditional Chinese medicine processing method | |
| Sadiq et al. | Treating hyperglycemia from Eryngium caeruleum M. Bieb: In-vitro α-glucosidase, antioxidant, in-vivo antidiabetic and molecular docking-based approaches | |
| JP5667561B2 (en) | Neurite outgrowth agent, memory improving agent, anti-Alzheimer agent containing 4'-demethylnobiletin or 4'-demethyltangeretin as an active ingredient, and method for producing the same | |
| CN101899070B (en) | Preparation method for fast separating flavonoid glycosides from oil-tea-cakes with medium pressure column | |
| CN104341430B (en) | A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes | |
| CN102701938A (en) | Method for extracting and purifying phloretin from Malus toringoides(Rehd.) Hughes. and Malus tiansitoria(Batal.)Schneid. | |
| CN105503807B (en) | A kind of catechin derivative of the trans caffeic acid ester of entitled epicatechin and its preparation method and application | |
| Ye et al. | Total Flavonoids of Crocus sativus Petals Release tert‐Butyl Hydroperoxide‐Induced Oxidative Stress in BRL‐3A Cells | |
| CN102241684B (en) | Preparation method of parthenolide | |
| CN106279332A (en) | Triterpenoid compound Antcin K and liver-protecting activity thereof and application | |
| CN109438213B (en) | Isopentenyl chalcone compound and preparation method thereof | |
| CN104800252A (en) | Refined polyphenol with tumor suppression function as well as preparation method and application of polyphenol | |
| CN105348333A (en) | Allyl phenol bioside compound and preparation method and application thereof | |
| Victório et al. | Flavonoid extraction from Alpinia zerumbet (Pers.) Burtt et Smith leaves using different techniques and solvents | |
| Hong et al. | Growth inhibition and G1 cell cycle arrest mediated by 25-methoxyhispidol A, a novel triterpenoid, isolated from the fruit of Poncirus trifoliata in human hepatocellular carcinoma cells | |
| Xiao et al. | Microbial transformation of quercetin and its prenylated derivatives | |
| CN102772501A (en) | Rheum emodi Wall. extract and its preparing method | |
| CN108129439A (en) | The preparation method and applications of two bis-flavonoids with antitumor activity in a kind of Chinese podophyllum root | |
| CN110041388A (en) | A kind of flavone compound or its pharmaceutically acceptable salt, ester or solvate and its extracting method and purposes | |
| Gevrenova et al. | A phytochemical study and antioxidant potential of Portulaca oleracea L.(Purslane) grown wild in Bulgaria and Greece | |
| Zhao et al. | A novel estimation method of total flavonoids in edible medicinal mulberry leaves by ultrasound-assisted hydroalcohol-acid extraction and HPLC-DAD. | |
| CN106565811B (en) | The extracting method of the hypoglycemic active ingredient of Chinese yam aerial part and application | |
| Victório et al. | Flavonoids extraction from Alpinia zerumbet (Pers.) Burtt et Smith leaves using different procedures | |
| CN103013943A (en) | Dryopteris erythrosora chalcone synthase gene and coded protein thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for processing traditional Chinese medicine Granted publication date: 20110817 Pledgee: Bank of China Limited Zhangshu sub branch Pledgor: JIANGXI ZHANGSHU TIANQITANG TRADITIONAL CHINESE MEDICINE DECOCTION PIECES Co.,Ltd. Registration number: Y2024980039770 |